To observe the clinical efficacy of grey screening method (GSC) on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer.

A total of 103 hospitalized patients with advanced non-small cell lung cancer treated in Tianjin People's Hospital from January 1, 2017 to June 31, 2018 were selected and randomly divided into either a treatment group (52 cases) or a control group (51 cases). Patients in the treatment group were given GSC combined with intravenous chemotherapy with paclitaxel and cisplatin, while patients in the control group received intravenous chemotherapy with paclitaxel and cisplatin only. After two cycles of chemotherapy, the curative effect, Karnofsky performance scale (KPS) score, adverse reactions and quality of life were compared between the two group.

Fifty patients in the treatment group completed the treatment, including 7 cases with complete response, 22 with partial response, 19 with stable disease and 2 with progressive disease. In the control group, 50 cases completed the treatment, including 3 cases with complete response, 16 with partial response, 26 with stable disease and 5 with progressive disease. The total effective rate of the treatment group (58%) was significantly higher than that in the control group (38%; P＜0.05). In terms of adverse reactions, manageable mild bone marrow suppression was observed in the treatment group. Compared with the control group, the treatment group had a significantly reduced incidence of adverse reactions such as gastrointestinal reactions and liver dysfunction (P＜0.05). The KPS score of the treatment group was significantly higher than that of the control group after treatment [(70.91±14.45) vs (55.71±11.21), P＜0.05]. Subgroup analysis showed that the KPS scores of patients with syndrome of deficiency of both Qi and Yin and syndrome of endogenous heat due to Yin deficiency in the treatment group were significantly higher than those of the control group [(72.22±13.02) vs (57.14±7.56) and (72.00±17.89) vs (53.75±10.61), respectively; P＜0.05 for both]. Regarding the quality of life with malignant tumors, compared with the control group, the scores of body, role, mood, and general health status in the treatment group were significantly improved, and the scores of insomnia, constipation, diarrhea, and poor appetite were significantly decreased (P＜0.05).

GSC combined with chemotherapy in patients with advanced non-small cell lung cancer has reliable efficacy and can reduce the adverse reactions of chemotherapy and improve the quality of life.